1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Patient characteristics
Characteristics n = 113
Age (mean) (yr) 55.2 (SD, 11.5)
Male (No.) (%) 78 (69%)
Race 
 White 99 (87.6%)
 African American 1 (0.9%)
 Asian 1 (0.9%)
 Other 3 (2.7%)
 Unknown 9 (8.0%)
Treatment regimen 
 Cohort A 30 (26.5%)
 Cohort B 26 (23.0%)
 Cohort B2 23 (20.4%)
 Cohort B3 19 (16.8%)
 Cohort C 15 (13.3%)
Median PFS (IQR) (days) 106 (56–150.5)
Median OS (IQR) (days) 207.5 (150.5–393.5)

Characteristics	n = 113
Age (mean) (yr)	55.2 (SD, 11.5)
Male (No.) (%)	78 (69%)
Race
White	99 (87.6%)
African American	1 (0.9%)
Asian	1 (0.9%)
Other	3 (2.7%)
Unknown	9 (8.0%)
Treatment regimen
Cohort A	30 (26.5%)
Cohort B	26 (23.0%)
Cohort B2	23 (20.4%)
Cohort B3	19 (16.8%)
Cohort C	15 (13.3%)
Median PFS (IQR) (days)	106 (56–150.5)
Median OS (IQR) (days)	207.5 (150.5–393.5)